Nestlé Uses AI to Target GLP-1 Users

Nestlé is aiming to capitalize on the GLP-1 weight‑loss drug wave by using AI and nutritional science to create products for users of Ozempic and Wegovy, including formulations to mitigate side effects such as muscle and facial fat loss. The company views the rising GLP‑1 market as a major opportunity, with tens of millions of potential consumers and AI helping to accelerate research and tailor offerings. Separately, Eli Lilly and Novo Nordisk remain locked in a high-stakes market dynamic, with Lilly posting stronger quarterly revenue and a looming competitive spotlight as Novo Nordisk cuts its full‑year outlook and faces a patent-style advertising dispute over drug data. AstraZeneca signals that the GLP-1 arena extends beyond weight management, as executives stress differentiating strategies in this expanding field. Amid this growth, regulators warn about counterfeit and falsified GLP-1 medicines entering supply chains, underscoring safety and quality concerns as demand climbs. Overall, the GLP-1 landscape is merging rapid pharmaceutical innovation with consumer‑facing nutrition strategies and vigilant regulatory oversight.